State Street’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-511,169
| Closed | -$1.89M | – | 3813 |
|
|
2017
Q4 | $1.89M | Buy |
511,169
+57,061
| +13% | +$234K | ﹤0.01% | 3205 |
|
|
2017
Q3 | $1.86M | Buy |
454,108
+42,809
| +10% | +$164K | ﹤0.01% | 3235 |
|
|
2017
Q2 | $1.53M | Buy |
411,299
+377,410
| +1,114% | +$1.5M | ﹤0.01% | 3238 |
|
|
2017
Q1 | $140K | Buy |
33,889
+22,700
| +203% | +$95.4K | ﹤0.01% | 3527 |
|
|
2016
Q4 | $47K | Sell |
11,189
-1
| -0% | -$6 | ﹤0.01% | 3567 |
|
|
2016
Q3 | $109K | Hold |
11,190
| – | – | ﹤0.01% | 3442 |
|
|
2016
Q2 | $63K | Sell |
11,190
-260,094
| -96% | -$1.77M | ﹤0.01% | 3574 |
|
|
2016
Q1 | $2.06M | Buy |
271,284
+1,307
| +0.5% | +$10.1K | ﹤0.01% | 2994 |
|
|
2015
Q4 | $3.6M | Buy |
269,977
+6,195
| +2% | +$107K | ﹤0.01% | 2714 |
|
|
2015
Q3 | $4.34M | Buy |
263,782
+29,024
| +12% | +$595K | ﹤0.01% | 2592 |
|
|
2015
Q2 | $5.27M | Buy |
234,758
+73,389
| +45% | +$1.16M | ﹤0.01% | 2596 |
|
|
2015
Q1 | $1.58M | Buy |
161,369
+35,846
| +29% | +$352K | ﹤0.01% | 3107 |
|
|
2014
Q4 | $1.43M | Buy |
125,523
+4,086
| +3% | +$44.3K | ﹤0.01% | 3163 |
|
|
2014
Q3 | $1.4M | Buy |
121,437
+11,742
| +11% | +$179K | ﹤0.01% | 3157 |
|
|
2014
Q2 | $2.13M | Buy |
109,695
+104,838
| +2,158% | +$1.85M | ﹤0.01% | 3041 |
|
|
2014
Q1 | $87K | Hold |
4,857
| – | – | ﹤0.01% | 3513 |
|
|
2013
Q4 | $51K | Hold |
4,857
| – | – | ﹤0.01% | 3536 |
|
|
2013
Q3 | $61K | Sell |
4,857
-83
| -2% | -$874 | ﹤0.01% | 3504 |
|
|
2013
Q2 | $46K | Buy |
+4,940
| New | +$63.5K | ﹤0.01% | 3455 |
|
State Street's CASC Position: Q1 2018 in Review
State Street sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 511,169 shares — an estimated $1.89M sold.
State Street first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $5.27M in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- State Street reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- State Street sold 511,169 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $1.89M.
- State Street first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- State Street's Cascadian Therapeutics, Inc. position peaked at $5.27M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on State Street's 13F filing for Q1 2018, filed 15 May 2018.